Edgewise Therapeutics Inc (EWTX)
Edgewise Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing treatments for muscle disorders. Its lead candidate, sevasemten, is an oral small-molecule therapy in Phase II clinical trials and is being developed to address dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy. The company is also advancing EDG-7500, a small molecule in Phase I trials for hypertrophic cardiomyopathy and other severe cardiac disorders, as well as EDG-15400 for heart failure with preserved ejection fraction. In addition, Edgewise is building a precision medicine pipeline aimed at key muscle proteins and modulators for genetically defined muscle diseases. The company was incorporated in 2017 and is based in Boulder, Colorado.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-EWTX
|
$32.86
|
-16.7% Downside
|
Fair
|
$49.92
|
26.5% Upside
|
Undervalued
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-24.3x
|
8.7x
|
—
|
4.176 B
|
3.774 B
|
0.1%
|
62.4%
|
97.2
|
—
|
84.6%
|
